CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The Canadian Cancer Trials Group (CCTG) at Queens University is currently seeking a visionary cancer trialist for the position of Senior Investigator (SI). The new SI will play a critical role for CCTG, acting as a co-principal investigator of numerous individual trials and a leader within the CCTG program and scientific committees.
As part of our commitment to promote capacity building in the Canadian cancer research landscape, the CIHR Institute of Cancer Research (CIHR-ICR), in partnership with the Ontario Institute for Cancer Research and Terry Fox Research Institute, as well as in-kind partners, the Canadian Cancer Society and Cancer Research Society, is pleased to announce the open call for applications for its annual Early Career Researcher (ECR) Workshop.
CCTG is thrilled to welcome Lindsay Clarke, who will be supporting the Genitourinary Disease Site Committee as a Patient Representative.
Lindsay Clarke is a registered nurse and mother who lives in Fort Saskatchewan, Alberta. She has a passion for caring for others and she has been volunteering with Prostate Cancer Canada (Cancer Canada) for the last 14 years. Prostate cancer is common amongst the men in Lindsay’s family, she tragically lost her father to prostate cancer in 2010, he was only 58 years old.
Congratulations to Dr Michael Ong, who has received $2,487,015 over 7 years from the Canadian Institutes of Health Research (CIHR) to support the CCTG PR26 (TRIPLE-SWITCH) prostate clinical trial.
Plasma versus tissue tumor mutational burden as Biomarkers of Durvalumab plus Tremelimumab response in patients with metastatic colorectal cancer in the CO26 trial.
Jonathan M. Loree, Emma Titmuss, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, Shakeel Virk, Young S. Lee, Kimberly Banks, Katie Quinn, Aly Karsan, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen
Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the CCTG LY12 clinical trial
The CEC6 trial, a Phase III intergroup study of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant pcv chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low-grade glioma, has closed to further accrual as the study has met the target sample size.
